Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery

View original at globenewswire.com
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery Dublin, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia-Pacific is the fastest-growing region with a 14.12% CAGR

    80% confidence

  • More than 15 FDA clearances since 2024 have tied targeted drugs to specific biomarker tests, widening the addressable patient pool for precision oncology

    80% confidence

  • Next-generation sequencing captured 33.78% of the precision medicine market share in 2025

    80% confidence

  • Guardant Health's Shield blood test detects colorectal cancer with 83% sensitivity in average-risk adults

    80% confidence

  • North America led the precision medicine market with a 47.85% revenue share in 2025

    80% confidence

  • SomaLogic measures 10,000 proteins from a microliter sample, producing high-density data that AI models translate into early disease risk scores

    80% confidence

  • The Precision Medicine market size in 2026 is estimated at USD 125.71 billion, growing from 2025 value of USD 110.68 billion with 2031 projections showing USD 237.28 billion, growing at 13.58% CAGR over 2026-2031

    80% confidence

  • China's Human Genome Project 2 plans to sequence 80 million genomes, creating the world's largest reference panel for variant interpretation

    80% confidence

  • Artificial intelligence and machine learning is the fastest-growing segment at a 17.62% CAGR

    80% confidence

  • Japan has committed to analyze 100,000 cancer genomes under a national program to guide targeted therapy development

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery — Source | Via News | Via News